The vaccine is based on Sanofi’s recombinant protein-based technology, used to produce an influenza vaccine, as well as GSK’s pandemic adjuvant technology.
Sanofi is responsible for the clinical development and registration of the vaccine. The company expects to begin a Phase I / II clinical trial in September, followed by a Phase III trial by the end of the year.
If positive trial data are obtained, regulatory approval is anticipated by the first half of next year.
Simultaneously, the companies are working to scale up production of the antigen and adjuvant to generate up to one billion doses a year overall.
GSK Vaccines president Roger Connor said: “We believe that this adjuvanted vaccine candidate has the potential to play a significant role in overcoming the Covid-19 pandemic, both in the UK and around the world.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“We thank the UK Government for confirmation of purchasing intent, which supports the significant investment we are already making as a company to scale up development and production of this vaccine.”
The companies added that discussions are underway with global organisations, the US and the EU Commission, including France and Italy, for the vaccine supply.
Sanofi and GSK intend to deliver a portion of total available global supply capacity in 2021 / 22 to the Access to Covid‐19 Tools (ACT) Accelerator initiative.
The initiative is a global partnership between governments, health organisations, businesses and philanthropies to speed-up development, manufacturing and equitable access to tests, treatments and vaccines for Covid-19.
For the UK, this deal marks the fourth type of immunisation against Covid-19, with a total of 250 million doses.
In addition, a deal has also been signed for access to Covid-19 neutralising antibodies from AstraZeneca, and 100 million doses of the Oxford Covid-19 vaccine.